Axova Research PT-141 (Bremelanotide) is a high-purity synthetic peptide signaling molecule structurally derived as a metabolite of Melanotan 2. In cellular, neurochemical, and physiological research models, PT-141 is widely investigated for its unique cyclic lactam structure, which confers heightened metabolic stability and an extended biological half-life against rapid enzymatic cleavage compared to endogenous linear a-MSH.

Unlike native melanocortin peptides that act broadly across all receptor subtypes, PT-141 demonstrates distinct receptor selectivity by acting as a high-affinity agonist primarily at central melanocortin-3 (MC3R) and melanocortin-4 (MC4R}) pathways located within the central nervous system. Because it lacks a C-terminal amide sequence that drives peripheral MC1R activation, PT-141 allows researchers to isolate central neuroendocrine and autonomic responses without inducing significant cutaneous melanogenesis. In laboratory settings, this compound serves as a primary subject for analyzing central receptor binding dynamics, hypothalamic signal transduction, and downstream physiological feedback mechanisms in animal models.